Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
NCT ID: NCT01467401
Last Updated: 2017-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
292 participants
INTERVENTIONAL
2002-08-19
2003-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes
NCT01486875
Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs
NCT01486862
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
NCT00729898
Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
NCT00657319
Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects
NCT01486888
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
biphasic insulin aspart
Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
B
biphasic human insulin
Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biphasic insulin aspart
Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
biphasic human insulin
Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Insulin treatment for the pase 3 months
* HbA1c (glycosylated haemoglobin) below 13%
* BMI (Body Mass Index) below 40 kg/m\^2
* Ability and willingness to perform self-blood glucose monitoring
Exclusion Criteria
* Treatment of OHAs (Oral Hypoglycaemic Agents) within 4 weeks prior to this trial
* Total daily insulin dosage less than or equal to 1.8 IU/kg
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Århus C, , Denmark
Novo Nordisk Investigational Site
Esbjerg, , Denmark
Novo Nordisk Investigational Site
Herning, , Denmark
Novo Nordisk Investigational Site
Holbæk, , Denmark
Novo Nordisk Investigational Site
Næstved, , Denmark
Novo Nordisk Investigational Site
Randers, , Denmark
Novo Nordisk Investigational Site
Silkeborg, , Denmark
Novo Nordisk Investigational Site
Skive, , Denmark
Novo Nordisk Investigational Site
Viborg, , Denmark
Novo Nordisk Investigational Site
Åsgårdstrand, , Norway
Novo Nordisk Investigational Site
Bekkestua, , Norway
Novo Nordisk Investigational Site
Bergen, , Norway
Novo Nordisk Investigational Site
Haugesund, , Norway
Novo Nordisk Investigational Site
Hønefoss, , Norway
Novo Nordisk Investigational Site
Moelv, , Norway
Novo Nordisk Investigational Site
Oslo, , Norway
Novo Nordisk Investigational Site
Tromsø, , Norway
Novo Nordisk Investigational Site
Vennesla, , Norway
Novo Nordisk Investigational Site
Arvika, , Sweden
Novo Nordisk Investigational Site
Avesta, , Sweden
Novo Nordisk Investigational Site
Bjuv, , Sweden
Novo Nordisk Investigational Site
Broby, , Sweden
Novo Nordisk Investigational Site
Färgelanda, , Sweden
Novo Nordisk Investigational Site
Gothenburg, , Sweden
Novo Nordisk Investigational Site
Gothenburg, , Sweden
Novo Nordisk Investigational Site
Gothenburg, , Sweden
Novo Nordisk Investigational Site
Gothenburg, , Sweden
Novo Nordisk Investigational Site
Grästorp, , Sweden
Novo Nordisk Investigational Site
Habo, , Sweden
Novo Nordisk Investigational Site
Härnösand, , Sweden
Novo Nordisk Investigational Site
Hässleholm, , Sweden
Novo Nordisk Investigational Site
Helsingborg, , Sweden
Novo Nordisk Investigational Site
Jönköping, , Sweden
Novo Nordisk Investigational Site
Karlstad, , Sweden
Novo Nordisk Investigational Site
Karlstad, , Sweden
Novo Nordisk Investigational Site
Kristianstad, , Sweden
Novo Nordisk Investigational Site
Kristinehamn, , Sweden
Novo Nordisk Investigational Site
Kungsbacka, , Sweden
Novo Nordisk Investigational Site
Malmo, , Sweden
Novo Nordisk Investigational Site
Mellerud, , Sweden
Novo Nordisk Investigational Site
Mölndal, , Sweden
Novo Nordisk Investigational Site
Norrköping, , Sweden
Novo Nordisk Investigational Site
Örebro, , Sweden
Novo Nordisk Investigational Site
Örebro, , Sweden
Novo Nordisk Investigational Site
Örebro, , Sweden
Novo Nordisk Investigational Site
Östersund, , Sweden
Novo Nordisk Investigational Site
Östersund, , Sweden
Novo Nordisk Investigational Site
Säffle, , Sweden
Novo Nordisk Investigational Site
Skövde, , Sweden
Novo Nordisk Investigational Site
Stockholm, , Sweden
Novo Nordisk Investigational Site
Tomelilla, , Sweden
Novo Nordisk Investigational Site
Torsby, , Sweden
Novo Nordisk Investigational Site
Trollhättan, , Sweden
Novo Nordisk Investigational Site
Trollhättan, , Sweden
Novo Nordisk Investigational Site
Tyresö, , Sweden
Novo Nordisk Investigational Site
Uddevalla, , Sweden
Novo Nordisk Investigational Site
Värnamo, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIASP-1394
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.